Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013

Jul 31, 2013 2:34:25 PM

CSO to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production Bottlenecks

Geneva, Switzerland (PRWEB) July 31, 2013 – Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company will present data on the SURE CHO-Mplus™ Library at the Bioprocessing Summit being held August 19 – 23 at the Renaissance Boston Waterfront Hotel in Boston, Massachusetts. Selexis’ chief scientific officer, Pierre-Alain Girod, PhD, will present, “A CHO-M Cell Combinatorial Library for the Improved Selection of Recombinant Protein Production Clones,” on Wednesday, August 21 at 11:45 AM as part of the Cell Line Development tract.

Additionally, a poster presentation with data from the recently launched SURE CHO-Mplus™ Library, “CHO Cell Library for the Selection of Improved Recombinant Therapeutic Protein Production,” is scheduled to be presented at the conference. The poster presentation will discuss new solutions that address a broad range of recombinant protein secretion issues.

Presentation Abstract:
With some proteins, optimal productivity requires more than elevated transcription. Metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications can all effect output. Utilizing the CHO-M genome and transcriptome, we have engineered a combinatorial CHO cell library to address a broad range of these production bottlenecks.

Poster Abstract:
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene, thus boosting the overall expression of a therapeutic protein drug in mammalian cells.However, there are additional cellular bottlenecks, notably in the molecular machinery of the secretory pathways. Most importantly, mammalian cells have some limitations in their intrinsic capacity to manage a high level of protein synthesis as well as folding recombinant proteins. These bottlenecks often lead to increased cellular stress and, therefore, low production rates.Dr. Girod and the company’s VP of business development, Andrew Sandford, will be available for questions at the Selexis Booth 7 from August 19 - 23. Please see conference website for complete schedule.